Direct compression of the Chuanyu Jinqiaomai Powder veterinary-grade API is evaluated only after laser diffraction particle size analysis and moisture sorption profiling, because the primary particle size distribution determines whether a low-shear tumble blender or a high-shear granulator is required. For tablet core blends in which the API accounts for 20.0–40.0% w/w, the dried powder is passed through a 0.8 mm conical mill at 2,000 rpm before preblending with microcrystalline cellulose and croscarmellose sodium. Pilot compression is conducted on an instrumented rotary press fitted with 8 mm round, concave-tipped tooling; compression force is ramped between 8 kN and 15 kN. Weight variation, thickness, and breaking force are sampled every 15 min, and acceptance is based on the uniform dosage unit criterion in USP <905> with an acceptance value of ≤15.0. Friability is held to ≤1.0% after 100 revolutions per Ph. Eur. 2.9.7, and disintegration is tested in water at 37 ± 2 °C with a limit of ≤15 min per USP <701>. If the API powder retains moisture above 5.0% w/w as measured by USP <731>, die-wall adhesion and capping become more frequent; drying to 2.0–4.0% w/w before compression is therefore specified. For formulations that exhibit capping at higher compression speed, croscarmellose sodium is increased from 2.0% to 4.0% w/w and press speed is reduced from 60 rpm to 40 rpm until formulation hardness stabilizes.

Wet granulation is selected when the raw powder shows a compressibility index above 25% per USP <1174> or when the API dose is too low to ensure geometric dilution in a direct compression blend. Aqueous binder solution containing povidone K30 at 3.0–5.0% w/w is sprayed onto the fluidized bed at an inlet air temperature of 60–70 °C and a product temperature of 35–45 °C. The granule endpoint is controlled by loss on drying at 2.0–4.0% w/w; lower values increase fines and capping, while higher values promote picking during long compression runs. Magnesium stearate is restricted to 0.5–0.75% w/w and final bin blending is limited to 3–5 min at 25 rpm in a 300 L bin blender, because over-lubrication produces a hydrophobic film that lowers tablet tensile strength and retards disintegration. Published data for this specific API in all matrix configurations is limited; feasibility batches are therefore used to confirm the assigned limits before commercial scale-up.

When Terminal Sterilization Is Not Feasible for the Soluble API Fraction

Preformulation solubility screening in Water for Injection at 25 ± 2 °C and 2–8 °C determines whether the API fraction can be formulated as a true solution or requires a lyophilized powder for reconstitution. If the saturated solubility at target dose volume is below 5.0 mg/mL, pH adjustment is evaluated across pH 4.0–7.5 using 0.1 M hydrochloric acid or sodium hydroxide; osmolality is then adjusted with sodium chloride or dextrose to 280–320 mOsm/kg per Ph. Eur. 2.2.35. Aseptic processing of the finished solution is performed in Grade A laminar airflow with Grade B background per EU GMP Annex 1 §4.18, because terminal sterilization at 121 °C for 15 min is not considered feasible when assay loss or degradation product formation exceeds the permitted threshold. The bulk solution is passed through a 0.22 μm polyvinylidene fluoride or polyethersulfone membrane; bacterial retention is supported by filter validation using ASTM F838-20, and pre- and post-filtration integrity testing is conducted by bubble point or pressure hold. Post-filtration assay recovery of the API is set at ≥95.0%, and filtrate temperature is held below 25 °C during recirculation to limit adsorptive loss on membrane surfaces.

Particulate matter for small-volume parenteral containers is controlled to ≤6000 particles ≥10 μm and ≤600 particles ≥25 μm per container by light obscuration per USP <788>. Bacterial endotoxin is limited according to dose, and Water for Injection used in the process meets <0.25 EU/mL per Ph. Eur. 2.6.14; sterility testing of finished product follows Ph. Eur. 2.6.1. Nitrogen overlay is applied during filling to maintain headspace oxygen below 2.0% v/v, and the filling line is set to 100% automated weight check at 1-second intervals for high-speed lines. Light-sensitive formulations are packed in amber Type I glass; container transmission limits are checked per USP <660>. Incompatibility with free metal ions is addressed by passivating stainless steel mixing vessels with 1.0% nitric acid at 60 °C for 30 min; if the API fraction contains polyphenolic moieties, the use of iron-based components in filler nozzles is avoided.

What Governs Content Uniformity in Low-Fill-Weight Capsule Operations?

In low-fill-weight capsule manufacturing, the API particle size is reduced so that no more than 150 μm D90 remains by laser diffraction per ISO 13320:2020, and the milled material is conditioned to 45–55% relative humidity at 25 °C before blending. For API mass fractions below 5.0% w/w of the fill weight, geometric dilution in a low-shear V-blender is required; the first preblend is passed through a 0.5 mm sieve before addition to a final blend. Blend uniformity is evaluated by sampling at 10 equally spaced positions, with a target relative standard deviation of ≤5.0% and a finished product acceptance value of ≤15.0 per USP <905>. Fill weight control tolerance is set at ±3.0% per capsule, and empty two-piece hard gelatin or hypromellose shells are stored at 45–55% RH to prevent brittle fracture or softening. Capsule filling on a dosing-disc or tamping pin machine is run at 30,000–60,000 capsules per hour depending on formulation flowability; frequent stops to clear powder build-up on the tamping pins are recorded as a processing bottleneck when static charge accumulates above 2 kV on the powder bed.

Dissolution is performed in 0.1 M hydrochloric acid at 37 ± 0.5 °C with paddle apparatus at 50 rpm per USP <711>; a Q value of 80% at 30 min is set only after a veterinary pharmacokinetic justification. Blend moisture specification is maintained below 4.0% w/w as measured by USP <731>, because free moisture above this level changes tamping-pin compression depth and produces inconsistent fill weights. Disintegration of the finished capsules follows USP <701> with a limit of ≤15 min in water at 37 ± 2 °C. If crosslinking of gelatin shells is suspected after storage at 40 °C and 75% RH, disintegration media containing pepsin or pancreatin may be required to differentiate shell crosslinking from formulation failure; the specific enzyme addition follows the relevant pharmacopoeial method for delayed-release gelatin capsules.

For reconstitution into drinking water or milk replacer, the API powder is granulated by fluid-bed top-spray processing at an inlet air temperature of 60–70 °C and a product temperature of 35–45 °C. Aqueous binder solution containing povidone K30 at 3.0–5.0% w/w is atomized at 1.0–2.0 bar, and the final granules are dried to 2.0–3.5% w/w loss on drying per USP <731>. Sieve analysis per USP <811> keeps the usable granule fraction between 0.15 mm and 0.85 mm; oversize material is dry-milled through a 1.0 mm screen at 1,500 rpm before final blending. A granule compressibility index below 15% per USP <1174> is targeted to maintain consistent sachet filling. Sachet packaging uses a foil laminate with water vapor transmission rate ≤0.1 g/m²/24 h at 38 °C and 90% RH per ASTM F1249-20. Reconstituted oral solution is limited to 24 h at 25 °C or 48 h at 2–8 °C; beyond these limits, microbial outgrowth and settling behavior require revalidation of preservative efficacy per USP <51>.

Palatability constraints in veterinary oral powders are evaluated by feed intake refusal and water consumption monitoring in target species; the formulation is not considered acceptable if voluntary intake falls below 80% of the untreated baseline over 72 h. Dry blending is preferred over aqueous granulation when the API has high water solubility and rapid recrystallization risk, but dry blending increases the hazard of segregation during transport; therefore, the finished sachet is subject to a vibration test at 25 Hz for 30 min per ASTM D999-08 to simulate vehicle transport. After vibration, the top, middle, and bottom powder samples must hold assay values within ±10.0% of label claim to pass.

Premix Homogeneity and Heat-Labile Feed Processing Boundaries

Medicated feed premix batches begin with a carrier dilution step in a double-ribbon mixer at 25 rpm for 10 min; the carrier is selected for oil absorption capacity of 1.0–3.0% w/w and particle size matching the final feed matrix. Homogeneity is confirmed by HPLC assay of 10 thief samples taken from the mixer dead zones, corners, and discharge path; the coefficient of variation is targeted at ≤5.0%, while CV values above 8.0% generally lead to rejected segments because of underdosing risk. Dust losses from the API powder fraction below 100 μm can exceed 2.0% w/w during open transfer, so closed discharge and vacuum transfer to the diluent mixer are specified. Batch records document mixer dead-space retention after discharge; retained material above 0.5% of batch mass triggers a cleaning and reconciliation investigation.

Steam pelleting introduces the main process conflict: conditioning at 80–85 °C for 30–60 s may exceed the thermal degradation threshold for heat-labile botanical API fractions. Low-temperature pellet conditioning in the 65–70 °C range is evaluated first, or the API is incorporated post-pelleting in a vacuum coater at 55–60 °C. Trace-mineral premixes containing high sulfate fractions are segregated from the API premix because hydrate formation and metal-catalyzed oxidation accelerate degradation. Equipment cleanup after medicated premix batches uses a flush of ground corn or wheat middlings at 25–50 kg per tonne of mixer capacity, with subsequent assay verification below the limit of quantification before non-medicated feed production. The analytical method for assay and homogeneity is validated according to VICH GL2, including recovery in the relevant feed matrix and specificity against common coccidiostats and organic acids.

Aqueous Vehicle Buffering Determines In-Use Stability in Drinking Water Dosing

Oral solution and drinking water dosing forms are developed as buffered aqueous vehicles because pH drift alters both solubility and preservative activity. Buffering efficacy is monitored by pH drift testing; a change of more than 0.5 pH units during 14 days at 40 ± 2 °C and 75 ± 5% relative humidity per VICH GL3 indicates insufficient buffer capacity. For weakly acidic API fractions that precipitate below pH 5.0, a 10–20 mM citrate buffer maintains pH 5.5–6.0 without exceeding oral electrolyte tolerance. The solution is filled into Type III soda-lime glass or high-density polyethylene containers; light transmission for glass is checked per USP <660>. In-use stability under farm conditions is challenged at 25 ± 2 °C for 24 h, with pH, assay, visual clarity, and total aerobic microbial count monitored at 0 h, 8 h, and 24 h.

Preservative systems containing sodium benzoate 0.1–0.2% w/v and potassium sorbate 0.1–0.2% w/v are active in the pH 4.5–5.5 window; if pH is raised above 6.0, benzoate antimicrobial activity declines sharply because the undissociated preservative fraction falls below 1.0% at 25 °C. Oxidation is controlled by nitrogen blanketing to maintain dissolved oxygen below 2.0 mg/L; if sodium metabisulfite is used at 0.1% w/v, benzaldehyde-based flavorings are excluded because sulfite adduct formation leads to organoleptic defects and assay loss. Passivation of stainless steel mixing vessels with 1.0% nitric acid at 60 °C for 30 min reduces iron and residual welding scale contamination. The finished solution is filtered through a 10 μm clarifying filter before bulk storage, and final packaging is protected from freeze-thaw cycling because recrystallization can shift the pH and produce visible crystalline particulates.